Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangiogenic-based treatment and systemic infla...

Full description

Bibliographic Details
Main Authors: Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Antiangiogenic-based chemotherapy
BRAF V600E mutations
Metastatic colorectal cancer
Systemic inflammation score
Online Access:https://doi.org/10.1186/s12885-020-07758-5

Internet

https://doi.org/10.1186/s12885-020-07758-5

Similar Items